vTv Therapeutics plans to keep its headquarters at its current location in High Point despite the building being purchased by a new owner and plans to end clinical trials for an Alzheimer's drug it has been developing, the company confirmed Tuesday.
The prospect of vTv Therapeutics moving its office from 4170 Mendenhall Oaks Parkway was raised after it was revealed Cambrex Corp. bought the 40,000-square-foot structure, along with its own building, for $10.2 million on April 6.
